Teva's Risperidone Injectable Wards Off Schizophrenia Relapse in Phase III

Teva Pharmaceutical announced positive results from its Phase III trial on a subcutaneous, long-acting injectable risperidone formulation in the treatment of schizophrenia.

The Phase III Risperidone Subcutaneous Extended-Release (RISE) study compared TV-46000/mdc-IRM, an injectable risperidone formulation, given once a month and once every two months with placebo in patients diagnosed with schizophrenia and have already taken risperidone for stabilization therapy. At week 24, the researchers found that those who took either the once-a-month or once-every-two-month doses experienced longer periods before relapsing.